- Home
- PRME vs EYPT Comparison
PRME vs EYPT Comparison
Compare PRME & EYPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PRME
- EYPT
- Stock Information
- Founded
- PRME 2019
- EYPT 1987
- Country
- PRME United States
- EYPT United States
- Employees
- PRME N/A
- EYPT N/A
- Industry
- PRME Medicinal Chemicals and Botanical Products
- EYPT Biotechnology: Laboratory Analytical Instruments
- Sector
- PRME Health Care
- EYPT Industrials
- Exchange
- PRME Nasdaq
- EYPT Nasdaq
- Market Cap
- PRME 191.7M
- EYPT 579.4M
- IPO Year
- PRME 2022
- EYPT 2005
- Fundamental
- Price
- PRME $3.14
- EYPT $10.15
- Analyst Decision
- PRME Buy
- EYPT Strong Buy
- Analyst Count
- PRME 6
- EYPT 8
- Target Price
- PRME $9.38
- EYPT $24.75
- AVG Volume (30 Days)
- PRME 3.7M
- EYPT 784.9K
- Earning Date
- PRME 08-04-2025
- EYPT 08-06-2025
- Dividend Yield
- PRME N/A
- EYPT N/A
- EPS Growth
- PRME N/A
- EYPT N/A
- EPS
- PRME N/A
- EYPT N/A
- Revenue
- PRME $3,846,000.00
- EYPT $56,042,000.00
- Revenue This Year
- PRME $104.12
- EYPT N/A
- Revenue Next Year
- PRME $196.78
- EYPT N/A
- P/E Ratio
- PRME N/A
- EYPT N/A
- Revenue Growth
- PRME 550.76
- EYPT 12.04
- 52 Week Low
- PRME $1.11
- EYPT $3.91
- 52 Week High
- PRME $6.75
- EYPT $13.99
- Technical
- Relative Strength Index (RSI)
- PRME 79.25
- EYPT 62.47
- Support Level
- PRME $2.28
- EYPT $8.96
- Resistance Level
- PRME $2.78
- EYPT $10.20
- Average True Range (ATR)
- PRME 0.34
- EYPT 0.76
- MACD
- PRME 0.12
- EYPT -0.03
- Stochastic Oscillator
- PRME 81.62
- EYPT 62.90
About PRME Prime Medicine Inc.
Prime Medicine Inc is a biotechnology company committed to delivering genetic therapies to address diseases by deploying gene editing technology, Prime Editing. The Prime Editing technology is a next-generation technology that can search and replace to restore normal genetic function in the genome and can treat a wide spectrum of diseases with high unmet medical needs and efficient and broad gene editing technology.
About EYPT EyePoint Pharmaceuticals Inc.
EyePoint Pharmaceuticals Inc is a pharmaceutical company. It is engaged in developing and commercializing ophthalmic products for the treatment of eye diseases. The company has developed FDA-approved sustained-release treatments in ophthalmology. Its pre-clinical development program is focused on using its core Durasert E and Verisome technology platforms to deliver drugs to treat wet age-related macular degeneration, glaucoma, osteoarthritis, and other diseases. Geographically, the firm has operational footprints in the U.S., China, and the UK. It generates a majority of its revenue from the U.S.